Company: ABBV
Filing Date: 2025-02-20
Form Type: 424B5
Source: 0001104659-25-015715
Chunk: 22

Company: AbbVie Inc.
Filing Date: 2025-02-20
Form: 424B5
Chunk 22
---
 DTC (or another depositary), the redemption of the Notes shall be done in accordance with the policies and procedures of the depositary. Any redemption or notice of redemption may, at AbbVie’s discretion, be subject to one or more conditions precedent, and, at AbbVie’s discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied.

Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the Notes or portions thereof called for redemption.

#### Open Market Purchases
AbbVie or any of its affiliates may at any time and from time to time purchase Notes in the open market or otherwise.

#### Sinking Fund
There is no provision for a sinking fund for any of the Notes.

#### Ranking
The Notes will be the Issuer’s unsecured, unsubordinated obligations, and will:

•

rank equally in right of payment with all of the Issuer’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations;

•

rank senior in right of payment to all of the Issuer’s future indebtedness that is subordinated to the Notes;

<div align='center'>S-14</div>

TABLE OF CONTENTS

•

be effectively subordinated in right of payment to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the assets securing such indebtedness; and

•

be structurally subordinated in right of payment to all existing and future indebtedness, liabilities and other obligations of the Issuer’s subsidiaries.

AbbVie derives substantially all of its operating income from, and holds substantially all of its assets through, its subsidiaries. AbbVie depends on distributions of cash flow and earnings from its subsidiaries in order to meet its payment obligations under the Notes and its other debt obligations. These subsidiaries are separate and distinct legal entities and will have no obligation to pay any amounts due on the Notes, or to provide AbbVie with funds for its payment obligations with respect thereto, whether by dividends, distributions, loans or otherwise. As a result, the Notes will be structurally subordinated to the liabilities of AbbVie’s subsidiaries, including trade payables. In addition, provisions of applicable law, such as those limiting the payment of dividends, could limit the ability of AbbVie’s subsidiaries to make payments or other distributions to it, and AbbVie’s subsidiaries could agree to contractual restrictions on their ability to pay dividends or make payments or other distributions